Phaco does not boost AMD progression

Article

No clear link between cataract surgery and progressive age-related macular degeneration (AMD) could be established by a study published in the February issue of Ophthalmology.

No clear link between cataract surgery and progressive age-related macular degeneration (AMD) could be established by a study published in the February issue of Ophthalmology.

Emily Y. Chew of the US National Eye Institute, Bethesda, Maryland and colleagues assessed the incidence of advanced AMD development among participants in the Age-Related Eye Disease Study (AREDS). Participants (n=4577; eyes, n=8050) - aged 55–80 years, with a visual acuity of 20/32 or better at baseline - were assessed for geographic atrophy, geographic atrophy of the central macula and neovascular AMD, and a history of cataract surgery was taken at six month intervals for up to 11 years. One thousand, one hundred and sixty-seven participants underwent cataract surgery during the study period.

The Cox proportional hazards model for right and left eyes showed no significant increase of risk for AMD after phacoemulsification. In the right eye, the hazard ratio for geographic atrophy, central geographic atrophy and neovascular AMD were 0.80, 0.87 and 1.20, respectively; in the left eye, these ratios were 0.94, 0.86 and 1.07, respectively. In eyes with pre-existing advanced AMD, the hazard ratios for the fellow eye were 0.98 for central geographic atrophy and 1.08 for neovascular AMD.

Contrary to previous study results, therefore, the team concluded that cataract surgery did not increase the risk of AMD progression significantly.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.